State Street Corp Sells 3,003 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

State Street Corp reduced its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 0.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,823,817 shares of the company’s stock after selling 3,003 shares during the period. State Street Corp owned approximately 2.80% of Day One Biopharmaceuticals worth $39,336,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after purchasing an additional 1,002 shares during the last quarter. Quest Partners LLC lifted its holdings in Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after buying an additional 7,668 shares in the last quarter. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals in the second quarter valued at about $113,000. Point72 DIFC Ltd bought a new position in shares of Day One Biopharmaceuticals in the 2nd quarter valued at about $124,000. Finally, Hsbc Holdings PLC bought a new position in Day One Biopharmaceuticals in the second quarter valued at approximately $163,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $12.79 on Friday. The company’s 50-day moving average price is $14.07 and its two-hundred day moving average price is $14.01. The stock has a market capitalization of $1.29 billion, a PE ratio of -12.42 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a one year low of $11.94 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to the consensus estimate of $15.05 million. During the same quarter in the prior year, the company earned ($0.54) EPS. On average, analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DAWN has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $35.71.

Insider Transactions at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $16.10, for a total transaction of $161,000.00. Following the transaction, the insider now directly owns 1,057,535 shares of the company’s stock, valued at approximately $17,026,313.50. The trade was a 0.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 51,745 shares of company stock worth $748,567 in the last ninety days. Insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.